FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Nurosene Health Inc. (the "Issuer").

Trading Symbol: MEND

Number of Outstanding Listed Securities: 33,237,502

Date: July 31, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

(a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.

(b) The term "Issuer" includes the Issuer and any of its subsidiaries.

(c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

   Subsequent to the Initial Public Offering that occurred in June, the Company has continued to primarily focus on supporting marketing initiatives and building of the Mobile Application.

The Company continues to build the brand through marketing initiatives that increase product awareness through driving traffic to the website and e-commerce store. The Company has managed to generate a relatively small number of sales through the website, which is expected, as the brand building and awareness initiatives are primary before customers will commit to purchases of supplements.

Mobile Application downloads and retention have increased through these marketing initiatives. The increase in user base supports our long term initiatives by providing important user data and metrics that can be used to develop AI and Machine Learning. In addition, the Mobile Application continues to be developed to add increased functionality to provide value to users.

The Mobile Application is also another channel for selling supplements and users that use the application will be directed to the most appropriate supplement after using the application for an appropriate time frame that allows the application to take in additional data points.

With users being active in the application and the ongoing marketing efforts, sales are expected to increase in August and September through the e-commerce platform.

The Company also continues to work with distributors to bring product to market outside of the independent e-commerce website. The Company continues to work on an online strategy i.e. Amazon and other health product websites; and applications for product to be sold in brick and mortar locations are in progress.

2. Provide a general overview and discussion of the activities of management.

Management continues to build out the business including the pursuit of its business objectives.

Management has sought to recruit in-house expertise to mitigate the reliance on third party consultants. Management continues to support application development through the build out of the engineering team to further bring development in house and no longer rely on third parties.

Management has cemented the marketing strategy with the hire of a Director of Growth Marketing to drive the presence in various marketing channels with a key focus on driving conversion of traffic to sales and downloads.

Management continues to seek and negotiate possible research partnerships that may result in novel technologies that can be included in the mobile application, or alternatively, support and validate current activities within the mobile application or formulations of the nutraceutical supplements. No such partnerships were finalized in July.

Management continues to build internal infrastructure to support the business and serve investors. Investor relations services have been retained in this month. Other initiatives include e-commerce support and marketing strategies to drive traffic to the online store and raise awareness of the Issuer, its brand and offerings.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

   The Issuer launched two nutraceutical products to market during June in the US.

   The Issuer now has both NPN (from Health Canada) and has begun to work towards launching these products in Canada, initially through an online store and then proceed to participate in the registration cycles for online and brick and mortar retailers.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

   There were no products or services discontinued.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

   The Issuer has not entered into significant new business relationships during the month of July.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

   No financing contracts or agreements have been cancelled.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

   The Issuer did not acquire any material assets.

8. Describe the acquisition of new customers or loss of customers.

   The Issuer generated new users of the mobile application through downloads.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

   No new developments of this nature occurred.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

The Issuer retained the services of an executive engineering hire.

There were no terminations or lay-offs during this month.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

No legal proceedings to note.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

The Issuer has no debt obligations.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds(1)
Common Shares	16,424	Warrants exercised during the month of July	Day to day operations

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

No loans to Related Persons.

16. Provide details of any changes in directors, officers or committee members.

No changes applicable.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Global Pandemic has given rise to mental health challenges that may be addressed through the use of the Mobile Application and nutraceutical supplements.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: July 6, 2021

Blake Sing
Name of Director or Senior Officer

(s) "*Blake Sing*"
Signature
CFO
Official Capacity

Issuer Details Name of Issuer Nurosene Health Inc.	For Month End June, 2021	Date of Report YY/MM/DD 21/08/09
Issuer Address 1655 Dupont St. – Suite 101		
City/Province/Postal Code Toronto, ON, M6P3T1	Issuer Fax No. ( )	Issuer Telephone No. 416 859 8838
Contact Name Blake Sing	Contact Position CFO	Contact Telephone No. 416 859 8838
Contact Email Address blake@nurosene.com	Web Site Address Nurosene.com	